• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2012 Product Image

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2012

  • Published: October 2012
  • 75 pages
  • Global Markets Direct

Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD). Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Post-Traumatic Stress Disorder READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Post-Traumatic Stress Disorder (PTSD) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Post-Traumatic Stress Disorder (PTSD) 9
Post-Traumatic Stress Disorder (PTSD) Therapeutics under Development by Companies 11
Post-Traumatic Stress Disorder (PTSD) Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Products under Development by Companies 19
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Post-Traumatic Stress Disorder (PTSD) Therapeutics Development 21
Nanotherapeutics, Inc. 21
Addex Pharmaceuticals 22
Catalyst Pharmaceutical Partners, Inc. 23
Biotie Therapies Corp. 24
NeuroNascent, Inc. 25
Azevan Pharmaceuticals, Inc. 26
Marinus Pharmaceuticals, Inc. 27
Post-Traumatic Stress Disorder (PTSD) – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
nepicastat - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PRX-3140 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NNI-351 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SRX-251 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SRX-246 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ketamine hydrochloride - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
mGluR7-NAM - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
aprepitant - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pregnenolone - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ganaxolone - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
MDMA - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
yohimbine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Neuropeptide-Y - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
guanfacine hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
mifepristone - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
cycloserine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
propranolol hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
carvedilol - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
propranolol hydrochloride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
prazosin hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
methylphenidate hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
D-Cycloserine + Prolonged Imaginal Exposure - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Drug Profile Updates 63
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Discontinued Products 66
Post-Traumatic Stress Disorder (PTSD) Therapeutics - Dormant Products 67
Post-Traumatic Stress Disorder (PTSD) – Product Development Milestones 68
Featured News & Press Releases 68
Aug 30, 2012: Armgo Pharma Announces Publication Of Data Related To New Approach For Treatment Of Stress-Induced Cognitive Disorders 68
Jun 20, 2011: Neuralstem On Schedule To Complete Phase Ia Trial Of NSI-189 In Major Depression 69
Apr 21, 2011: Marinus Announces Commencement Of Phase II Trial Of Ganaxolone In Posttraumatic Stress Disorder 69
Apr 07, 2011: Marinus Receives US Patent For Ganaxolone 70
Nov 03, 2008: Synosia Therapeutics Initiates Phase IIa Trial Of Nepicastat For Treatment Of Post-Traumatic Stress Disorder (PTSD) 70
Jul 24, 2008: US Department Of Defense To Fund Phase II Trial Of Synosia Therapeutics Nepicastat For Post-Traumatic Stress Disorder 71
Apr 28, 2005: SkyePharma and GlaxoSmithKline reach agreement on payment of royalties for Paxil CR. 72
Feb 25, 2004: Paxil CR receives US FDA approval for additional indication. 72
Feb 24, 2004: US FDA approves intermittent dosing of Paxil CR for the treatment of premenstrual dysphoric disorder (pmdd); new two-week regimens offer flexibility and convenience in alleviating emotional and physical symptoms of PMDD. 72
Jan 12, 2004: SkyePharma Welcomes Canadian Approval of Paxil CR. 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
Number of Products Under Development for Post-Traumatic Stress Disorder (PTSD), H2 2012 9
Products under Development for Post-Traumatic Stress Disorder (PTSD) – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Nanotherapeutics, Inc., H2 2012 21
Addex Pharmaceuticals, H2 2012 22
Catalyst Pharmaceutical Partners, Inc., H2 2012 23
Biotie Therapies Corp., H2 2012 24
NeuroNascent, Inc., H2 2012 25
Azevan Pharmaceuticals, Inc., H2 2012 26
Marinus Pharmaceuticals, Inc., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Drug Profile Updates 63
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Discontinued Products 66
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Dormant Products 67

List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2012 9
Products under Development for Post-Traumatic Stress Disorder (PTSD) – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos